Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.6%

87 terminated/withdrawn out of 423 trials

Success Rate

72.2%

-14.3% vs industry average

Late-Stage Pipeline

40%

168 trials in Phase 3/4

Results Transparency

10%

23 of 226 completed trials have results

Key Signals

20 recruiting23 with results61 terminated26 withdrawn

Enrollment Performance

Analytics

Phase 3

167(43.5%)

Phase 2

161(41.9%)

Phase 1

38(9.9%)

N/A

17(4.4%)

Phase 4

1(0.3%)

384Total

Phase 3(167)

Phase 2(161)

Phase 1(38)

N/A(17)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (423)

Showing 20 of 423 trials

NCT06809322Phase 3Recruiting

Vorasidenib Maintenance for IDH Mutant Astrocytoma

Role: lead

NCT07711080Not Yet Recruiting

Eortc MoBilE Device (EMBED)

Role: lead

NCT04685616Phase 3Recruiting

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Role: collaborator

NCT06246149Phase 3Recruiting

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Role: lead

NCT02834884Recruiting

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

Role: lead

NCT06219317Phase 2Active Not Recruiting

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

Role: lead

NCT02375204Phase 3Active Not Recruiting

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Role: collaborator

NCT06326190Phase 2Recruiting

177Lu-DOTATATE for Recurrent Meningioma

Role: lead

NCT05904119Phase 3Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Role: lead

NCT07234877Phase 2Not Yet Recruiting

Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

Role: lead

NCT06783348Phase 2Recruiting

Radiopharmaceutical Treatment of Advanced Kidney Cancer

Role: lead

NCT02856893Phase 2Completed

Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)

Role: lead

NCT05815927Phase 3Recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Role: lead

NCT04031677Phase 3Recruiting

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

Role: lead

NCT02799706Phase 3Active Not Recruiting

Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Role: lead

NCT05512364Phase 3Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Role: lead

NCT03134118Phase 2Active Not Recruiting

Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

Role: lead

NCT03515993Active Not Recruiting

Follow-up in Gynecological Cancer Survivors

Role: lead

NCT03859453Completed

Follow-up in Early and Locally Advanced Breast Cancer Patients